Kyselina tauroursodeoxycholová (TUDCA)


  1. Lepercq P, et al. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteriaBr J Nutr. (2005)
  2. Amaral JD, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acidJ Lipid Res. (2009)
  3. Invernizzi P, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosisHepatology. (1999)
  4. Setchell KD, et al. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosisGut. (1996)
  5. Zouboulis-Vafiadis I, Dumont M, Erlinger S. Conjugation is rate limiting in hepatic transport of ursodeoxycholate in the ratAm J Physiol. (1982)
  6. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s diseaseExp Neurol. (2001)
  7. Bernales S, Papa FR, Walter P. Intracellular signaling by the unfolded protein responseAnnu Rev Cell Dev Biol. (2006)
  8. Ozcan U, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetesScience. (2006)
  9. Ben Mosbah I, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusionCell Death Dis. (2010)
  10. Gao X, et al. The nephroprotective effect of tauroursodeoxycholic Acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stressBasic Clin Pharmacol Toxicol. (2012)
  11. Hertl M, et al. In vivo protection of the pig liver against ischemia/reperfusion injury by tauroursodeoxycholateLangenbecks Arch Surg. (1999)
  12. Anderson CD, et al. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allograftsLiver Transpl. (2011)
  13. Rodrigues CM, et al. Neuroprotection by a bile acid in an acute stroke model in the ratJ Cereb Blood Flow Metab. (2002)
  14. Amin A, et al. Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic miceJ Pathol. (2012)
  15. Achard CS, Laybutt DR. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistanceEndocrinology. (2012)
  16. Falasca L, et al. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipientsTransplantation. (2001)
  17. Marzioni M, et al. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ductsAm J Pathol. (2006)
  18. Henkel AS, et al. Reducing endoplasmic reticulum stress does not improve steatohepatitis in mice fed a methionine- and choline-deficient dietAm J Physiol Gastrointest Liver Physiol. (2012)
  19. Panella C, et al. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver diseaseItal J Gastroenterol. (1995)
  20. Solá S, et al. Membrane structural changes support the involvement of mitochondria in the bile salt-induced apoptosis of rat hepatocytesClin Sci (Lond). (2002)
  21. Schölmerich J, et al. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties–studies on isolated hepatocytes and lipid membrane vesiclesHepatology. (1984)
  22. Oelberg DG, Lester R. Cellular mechanisms of cholestasisAnnu Rev Med. (1986)
  23. Attili AF, et al. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acidsMed Hypotheses. (1986)
  24. Yousef IM, et al. Liver cell membrane solubilization may control maximum secretory rate of cholic acid in the ratAm J Physiol. (1987)
  25. Piazza F, et al. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates‘ protection of liver damage induced by chenodeoxycholic acidDig Liver Dis. (2000)
  26. Salen G, Tint GS, Shefer S. Treatment of cholesterol gallstones with litholytic bile acidsGastroenterol Clin North Am. (1991)
  27. Cetta F, Montalto G, Pacchiarotti MC. Gallstone opacification during cholelitholytic treatmentAm J Gastroenterol. (1997)
  28. Diehl AK. Epidemiology and natural history of gallstone diseaseGastroenterol Clin North Am. (1991)
  29. Attili AF, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of CholelithiasisHepatology. (1997)
  30. Therapy of gallstone disease: What it was, what it is, what it will be.
  31. Lanzini A, Northfield TC. Pharmacological treatment of gallstones. Practical guidelinesDrugs. (1994)
  32. Portincasa P, et al. Medicinal treatments of cholesterol gallstones: old, current and new perspectivesCurr Med Chem. (2009)
  33. Diseases of the Liver and Biliary System, Eleventh Edition.
  34. Lanzini A, Facchinetti D, Northfield TC. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administrationGastroenterology. (1988)
  35. Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol dietDig Dis Sci. (1982)
  36. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone diseaseScand J Gastroenterol Suppl. (1994)
  37. Bazzoli F, et al. Acquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acidsAm J Gastroenterol. (1995)
  38. Rodrigues CM, et al. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transitionJ Neurochem. (2000)
  39. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s diseaseProc Natl Acad Sci U S A. (2002)
  40. Ved R, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegansJ Biol Chem. (2005)
  41. Duan WM, et al. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson’s diseaseCell Transplant. (2002)
  42. Rodrigues CM, et al. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilizationMol Med. (2000)
  43. Ramalho RM, et al. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cellsJ Neurochem. (2006)
  44. Ramalho RM, et al. Apoptosis in transgenic mice expressing the P301L mutated form of human tauMol Med. (2008)
  45. Ramalho RM, et al. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cellsJ Neurochem. (2004)
  46. Rodrigues CM, et al. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholateBiochem Biophys Res Commun. (2001)
  47. Rodrigues CM, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in ratsProc Natl Acad Sci U S A. (2003)
  48. Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetesScience. (2004)
  49. Hirosumi J, et al. A central role for JNK in obesity and insulin resistanceNature. (2002)
  50. Urano F, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1Science. (2000)
  51. Rieusset J, et al. Reduction of endoplasmic reticulum stress using chemical chaperones or Grp78 overexpression does not protect muscle cells from palmitate-induced insulin resistanceBiochem Biophys Res Commun. (2012)
  52. da-Silva WS, et al. The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditureFEBS Lett. (2011)
  53. Tang C, et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stressDiabetologia. (2012)
  54. Boden G, et al. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjectsAm J Physiol. (1996)
  55. Kars M, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and womenDiabetes. (2010)
  56. Ockenga J, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humansJ Clin Endocrinol Metab. (2012)
  57. Brufau G, et al. Plasma bile acids are not associated with energy metabolism in humansNutr Metab (Lond). (2010)
  58. Sagar GD, et al. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activityMol Cell Biol. (2007)
  59. Watanabe M, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activationNature. (2006)
  60. Zhou L, et al. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulationDiabetes. (2010)
  61. Kim EK, et al. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growthPLoS One. (2017)
  62. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transitionOncogene. (2007)
  63. Krishna-Subramanian S, et al. UDCA slows down intestinal cell proliferation by inducing high and sustained ERK phosphorylationInt J Cancer. (2012)
  64. Goulet AC, et al. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cellsCarcinogenesis. (2005)
  65. Henzel K, et al. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acidBiochim Biophys Acta. (2004)
  66. Neuman MG, et al. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell lineGastroenterology. (1995)
  67. Leuschner U, et al. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effectsItal J Gastroenterol. (1995)
  68. Angelico M, et al. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantationItal J Gastroenterol Hepatol. (1999)
  69. Lindor KD, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisHepatology. (2009)
  70. Maggs JR, Chapman RW. An update on primary sclerosing cholangitisCurr Opin Gastroenterol. (2008)
  71. O’Brien CB, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot studyHepatology. (1991)
  72. Beuers U, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trialHepatology. (1992)
  73. Stiehl A, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study periodJ Hepatol. (1994)
  74. Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?Hepatology. (2009)
  75. Larghi A, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover studyAliment Pharmacol Ther. (1997)
  76. Crosignani A, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response studyDig Dis Sci. (1996)
  77. Crosignani A, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled studyHepatogastroenterology. (1998)